Embecta Corp (EMBC)vsIntuitive Surgical Inc (ISRG)
EMBC
Embecta Corp
$3.49
+6.08%
HEALTHCARE · Cap: $184.51M
ISRG
Intuitive Surgical Inc
$422.06
+1.14%
HEALTHCARE · Cap: $147.53B
Smart Verdict
WallStSmart Research — data-driven comparison
Intuitive Surgical Inc generates 915% more annual revenue ($10.58B vs $1.04B). ISRG leads profitability with a 28.1% profit margin vs 10.7%. EMBC trades at a lower P/E of 1.6x. ISRG earns a higher WallStSmart Score of 64/100 (C+).
EMBC
Buy53
out of 100
Grade: C-
ISRG
Buy64
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-37.4%
Fair Value
$7.32
Current Price
$3.49
$3.83 premium
Margin of Safety
+78.0%
Fair Value
$1896.32
Current Price
$422.06
$1474.26 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Attractively priced relative to earnings
Earnings expanding 82.7% YoY
Conservative balance sheet, low leverage
Strong operational efficiency at 30.9%
Safe zone — low bankruptcy risk
Large-cap with strong market position
Keeps 28 of every $100 in revenue as profit
Revenue surging 23.0% year-over-year
Areas to Watch
Distress zone — elevated risk
Smaller company, higher risk/reward
ROE of 0.0% — below average capital efficiency
Revenue declined 14.4%
Expensive relative to growth rate
Trading at 8.6x book value
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : EMBC
The strongest argument for EMBC centers on P/E Ratio, EPS Growth, Debt/Equity.
Bull Case : ISRG
The strongest argument for ISRG centers on Operating Margin, Altman Z-Score, Market Cap. Profitability is solid with margins at 28.1% and operating margin at 30.9%. Revenue growth of 23.0% demonstrates continued momentum.
Bear Case : EMBC
The primary concerns for EMBC are Altman Z-Score, Market Cap, Return on Equity.
Bear Case : ISRG
The primary concerns for ISRG are PEG Ratio, Price/Book, P/E Ratio. A P/E of 50.5x leaves little room for execution misses.
Key Dynamics to Monitor
EMBC profiles as a declining stock while ISRG is a growth play — different risk/reward profiles.
ISRG carries more volatility with a beta of 1.45 — expect wider price swings.
ISRG is growing revenue faster at 23.0% — sustainability is the question.
ISRG generates stronger free cash flow (809M), providing more financial flexibility.
Bottom Line
ISRG scores higher overall (64/100 vs 53/100), backed by strong 28.1% margins and 23.0% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Embecta Corp
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Embecta Corp (EMBC) is a prominent medical technology company dedicated to innovating insulin delivery systems for diabetes management. Established as a spin-off from Becton, Dickinson and Company, Embecta offers a wide range of advanced products, including state-of-the-art insulin pens and syringes, designed to improve patient outcomes. With a strong commitment to operational excellence and customer satisfaction, Embecta is strategically poised to leverage growth opportunities in the expanding diabetes care market, thereby reinforcing its leadership role in this critical sector.
Visit Website →Intuitive Surgical Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Intuitive Surgical, Inc. is an American corporation that develops, manufactures, and markets robotic products designed to improve clinical outcomes of patients through minimally invasive surgery, most notably with the da Vinci Surgical System.
Compare with Other MEDICAL INSTRUMENTS & SUPPLIES Stocks
Want to dig deeper into these stocks?